Medtech Leaders


Medtech Leaders Agenda

Tuesday 10 May 2022
(All times in GMT)


Welcome Address

Becky Johnson, Conference Director, LSX

Becky Johnson, Conference Director, LSX


Next Steps For Medtech: Convergence & Collaboration

  • How the NHS is approaching and managing convergence of technologies for health and care
  • Working to deliver better patient outcomes during a period of huge disruption and stress on the system
  • The role medical devices and health technologies are playing and how this is evolving
  • How the NHS is collaborating with the industry in different ways - partnerships, infrastructure, working with different
    existing and new ‘players’ in health and care
  • What more needs to be done?

Lord David Prior, Chairman, NHS

Lord David Prior, Chairman, NHS


Medtech’s Post COVID-19 Transformation Growth Strategy - How The ‘New Normal’ Became The ‘Here & Now’

To thrive in a post-Covid environment, medtech companies are taking a more nuanced approach to achieve long term growth, within an already rapidly changed landscape. A panel of commercial leaders discuss the current state of the exciting but challenging medtech market. Diving into the factors placing pressure on profitability, developments and strategies in medtech’s M&A market, and the emergent partnership models and deal-making strategies being leveraged as innovation continues apace.

  • What is the global medtech outlook post-COVID?
  • Europe vs US: How to remain competitive in varying markets and navigate the nuances associated with each
  • Evolution of medtech and convergence of new advanced technologies

Wilfred Van Zuilen, President EMEA, Zimmer Biomet
Xavier Bertrand, VP Healthcare Services and Alliances, Boston Scientific 

Wilfred Van Zuilen, President EMEA, Zimmer Biomet    Xavier Bertrand, VP Healthcare Services and Alliances, Boston Scientific


Morning Break


The Rise Of Business Development Opportunities Within Medtech & How Increased Innovation Is Catapulting Investment Into The Mainstream

The dearth of medtech deals in 2020 and 2021, combined with the pile up of cash reserves amongst leading players and interest from PE, shows promise for a healthy 2022. With non-emergency procedures deferred during the pandemic, a backlog of activity should power growth for medtech businesses. With the IPO market wide open and a buoyant stock market driven by SPACs growing medtech business have prospects for dual-track exit processes. A panel of medtech companies and stakeholders involved in recent mergers or acquisitions discuss the challenges of the current M&A market, the trend toward larger consolidation deals as well as bolt-on acquisitions, the increased activity of private equity, and the implications for innovation in the sector.

  • BD and partnering strategies from the top medtech commercial leaders
  • New areas of interest for potential new and exciting deals
  • The current medtech M&A landscape and drivers behind this
  • What are the most significant challenges medtech innovators encounter on the way to acquisition—where are the crucial inflection points in the journey?
  • Has a shrinking number of potential buyers created a greater challenge for innovators looking to be acquired?
  • How has the pattern of larger medtech players outsourcing R&D to external innovation impacted valuations for start-ups? What ramifications does this have for M&A volume and profitability?

Moderator: Gunnar Sachs, Partner, Clifford Chance
Charity Kufaas, VP BD and Strategy, Medtronic
Antonio Sanchez-Cordero, VP Business Development (M&A) Peripheral Intervention, BD
Rupert Winckler, Head of BD EMEA, Olympus
Thomas Hummel, Head of Strategy & Innovation, Siemens Healthineers 

Gunnar Sachs, Partner, Clifford Chance    Charity Kufaas, VP BD and Strategy, Medtronic    Antonio Sanchez-Cordero, VP Business Development (M&A) Peripheral Intervention, BD    Rupert Winckler, Head of EMEA Business Development, Olympus 300x    Thomas Hummel, Head of Strategy & Innovation, Siemens Healthineers


Patients, Providers, Payers And Product - The Pillars Underpinning Medtech Market Access Strategy

With limited budgets and increasing populations, there has been growing pressure on governments to provide the latest healthcare solutions for their countries. Market access planning and strategy has become more important than ever. As a result, healthcare systems around the world must focus on introducing technologies and treatments that can benefit the whole healthcare system, rather than cost reductions in one area alone. A panel of market access experts discuss the value of their devices and the challenges faced with a comprehensive market access strategy for their products.

  • Regulatory oversights and the challenges with new products
  • Understanding how the adoption journey differs depending on geographical market
  • Navigating local and national market access routes to benefit providers, payers and patients

Andrea Rappagliosi, VP Market Access, Public Affairs & Communications, EMEA, Canada and LATAM, Edwards Life Sciences
Dominique Gilsoul, Global Market Access Leader – Medical & Clinical Affairs, 3M 
Markus Ott, VP and Head of Global Market Access and Health Policy, Roche Diagnostics

Andrea Rappagliosi, VP Market Access, Public Affairs & Communications, EMEA, Canada and LATAM, Edwards Life Sciences    Dominique Gilsoul, Global Market Access Leader - Medical & Clinical Affairs - Healthcare Business Group, 3M    Markus Ott, VP and Head of Global Market Access and Health Policy, Roche Diagnostics


Lunch Break


The Medtech Investment Landscape – Rebounding, Evolving And Looking Forward

With total revenue of $510 billion in 2019, the medtech industry is increasing its share of the whole healthcare pie. Accelerated in 2020 & 2021 by the response to the global pandemic, technology has radically prompted disruption in fundamental ways, changing how healthcare is delivered to patients and creating new business models for innovative organisations. Never has the medtech industry been so attractive to investors, with companies showing potential for profitability, resiliency and growth fuelling an influx of capital. A panel of medtech investors discuss the dynamics shaping the industry, the real life implications of relevant trends and how investors and companies alike can ensure success in this ever growing market

  • Evolution product models as part of the medtech investment landscape
  • Innovative technologies to form part of attractive medtech investment opportunities
  • Putting consumers in control to develop a scalable and sellable product
  • Where is investment coming from: New funds and strategies within medtech investment

Alain Chevallier, Senior Partner, Truffle Capital
Brian Hakim, Director of International Business Development, MedtecX 
Baudouin Hue, Partner, Karista 
Anat Naschitz, Venture Partner, Orbimed 
Drew Burdon, Investment Manager, LSP 

Alain Chevallier, Senior Partner, Truffle Capital    Brian Hakim, Director Business Development, MedTecX    Baudouin Hue, Partner, Karista    Anat Naschitz, Managing Director, Orbimed-3    Drew Burdon, Investment Manager, LSP


Collaboration & Partnerships As The Route To Success – Creating ‘Beyond The Product’ Partnerships Between Providers And Medtech Players

Healthcare provision is undergoing unprecedented change and posing challenges for existing systems and providers. In Europe the projected gap between public health expenditure and government budgets is increasing and expected to reach 2% of GDP by 2030 in some countries. The opportunity lies in medtech companies working closely with healthcare providers to deliver not just equipment but other innovative services, that meet specific provider needs, offering significant opportunities on both sides.

  • The benefits of partnerships, beyond lowering fixed costs and improving service levels
  • Untapped revenue stream for medtech companies
  • Credibility obstacles with providers and how to overcome them

Moderator: Seamus Browne, Head of Industry Partnerships, Royal College of Surgeons 
John E. Milad, CEO, Quanta 
Sergio Levi, VP and Head of Strategic Alliances, Philips 
Bruce Lichorowic, President & CEO, Galen Robotics 

Seamus Browne, Head of Industry Partnerships, Royal College of Surgeons    John E. Milad, CEO, Quanta    Sergio Levi, Head of Corporate Ventures and Strategic Alliances, Philips    Bruce Lichorowic, President & CEO, Galen Robotics


Afternoon Break


Risk Reduction And Value Creation In Medtech Product Development - The Critical Role Of Preclinical Evaluation For Innovators, Investors And Stakeholders In The Healthcare Ecosystem

Innovation drives the advancement of health care. Far from a random moment of inspiration, successful innovation follows a disciplined development path. Before new technologies can reach the clinic, careful planning to define and complete the right preclinical studies with the right models is vital to satisfy the needs of key stakeholders and propel the program to the next stage. It is a pivotal phase of development that reduces risk and uncertainty while creating significant value. Join this session as we discuss the importance of innovation and all that it entails.

  • Key elements of the preclinical phase in Med Tech innovation
  • The vital importance of pathology evaluation, especially prior to final GLP studies
  • Observations on some of the latest trends in Med Tech and cutting-edge innovations coming through our lab

Robert Kieval, Chief Executive Officer, IMMR (now part of Veranex)

Robert Kieval, Chief Executive Officer, IMMR (now part of Veranex)


A Western Perspective On Crossborder Medtech Transactions With China

With the rapid growth of Chinese MedTech champions combined with a continued push for innovation, cross-border deals are increasingly playing a meaningful role in fueling innovation in China. However these deals, in light of the rapidly evolving landscape of leading players, local priorities and regulatory changes, are not without their challenges. This panel will feature Western MedTech executives with China experiences sharing their views of the China opportunities and challenges in order to help forge a successful pathway forward for Western MedTechs to capitalize on the China opportunity.

Moderator: Ari Silverman, Partner, Mavie Technologies 
Anne Osdoit, Partner, Sofinnova
Stephen Wildhirt, CEO, AdjuCor 
Jose (Pepe) Callo Gordo, Operating Partner, Valiance 
Georg Bortlein, Founder & President, High Life

Ari Silverman, Partner, MAVIE Technologies 2    Anne Osdoit, Partner, Sofinnova    Stephen Wildhirt, CEO, AdjuCor    Jose Calle Gordo, Managing Partner, Valiance    Georg Bortlein, Founder & President, High Life


Nothing Ventured Nothing Gained – Corporates Deploying Capital With Surgical Precision

Corporate venture capital is playing an increasingly crucial role in the medtech funding landscape and funds are more active than ever. An analysis of corporate investment trends showed medtech companies with investment units participated in rounds worth $1.2bn in the first three quarters of 2020. For the start ups, it still seems that corporate funds can be as, or more, risk averse, than traditional VCs but the prevalence of CVCs in new rounds is undeniable. A panel of leading CVC investors from multiple sectors consider the developing role of corporate and strategic capital in supporting innovation, and how SMEs can attract and engage with the corporate capital.

  • The role of the pandemic in the sectors growing interest in funding early stage device makers
  • Is the involvement of CVC in early stage funding likely to increase, or will the most CVC funding continue to focus on development of regulatory, reimbursement, and commercialisation pathways for more established medtechs?
  • What key factors would compel CVC to invest in an early stage medtechs, how much clinical data is necessary, and how can companies refine their pitch to attract strategic funding?

Jonathan Goldstein, Director, Global Technology Partnerships, Boston Scientific 
Oliver Keown, Director, Intuitive Ventures 
Andreas Wuepper, Director Investments Europe, Fresenius Medical Care Ventures

Jonathan Goldstein, Director, Global Technology Partnerships, Boston Scientific    Oliver Keown, Director, Intuitive Ventures    Andreas Wuepper, Partner, Fresenius


Networking Party


Wednesday 11 May 2022
(All times in GMT)


Welcome Address

Becky Johnson, Conference Director, LSX

Becky Johnson, Conference Director, LSX


The Devil Is In The Data: How The Medtech Sector Is Optimising Its Data Assets And Connecting With Consumers In A Wholly Patient Centric Approach

The surge in innovative medical technologies and devices in recent years has elevated patients to true stakeholders in the medtech ecosystem. Medical technology is gathering data around the clock all over the world, and this presents a massive opportunity for companies big and small to enhance their commercial strategies by better understanding the patients whom their products are serving. It is now imperative for device manufacturers, diagnostic companies, and health systems to design their products with the patient experience in mind: comfort, convenience, and connectivity all now constituting essential traits of a successful medical technology. Throw innovative technologies like AI and analytics into the mix, and the insights derivable from clinical, device and life-style data expand exponentially, as do the possibilities for their use. But is the medtech sector truly optimising its data assets and how are medtech manufacturers and innovators ensuring that patient-centricity is truly built into their products? A panel of medtech innovation leaders discuss.

  • Unlocking the full potential of health data, and new applications in 2022
  • Information is power: ethical data use and the importance of patient transparency
  • Regulatory and legal challenges limiting data access and the development of new solutions for treating patients and advanced treatments
  • How is the MDR going to look at data

Lucy Mackillop, Chief Medical Officer, Sensyne Health
Marc Julien, Co-CEO, Diabeloop
Laurent Vandebrouck, CEO, Chronolife 
Eliane Schutte, CEO, Xeltis 
Ian Crosbie, CEO, Sequana Medical 

Lucy Mackillop, Chief Medical Officer, Sensyne Health    Marc Julien, Co-CEO, Diabeloop    Laurent Vandebrouck, CEO, Chronolife    Eliane Schutte, CEO, Xeltis    Ian Crosbie, CEO Sequana Medical


Morning Break


Understanding The Challenges The Medtech Sector Is Facing As A Result Of The New EU Regulations & The UK’s Withdrawal From The EU

  • The Future of Legacy Devices under the new Medical Device Regulation (MDR)
  • The key changes brought about by the In Vitro Diagnostic Regulation (IVDR) and the challenges the Diagnostic Industry might face
  • Understanding the impact of the UK’s withdrawal from the EU on the MedTech Industry

Tina Amini, Medical Device Division Director, NDA Group

Tina Amini, Medical Device Division Director, NDA Group 300x


Navigating & Identifying The Pitfalls & Unforeseen Regulatory Complications Within The Context Of A Pandemic

Before the COVID-19 pandemic stole the show, the upcoming Medical Device Regulation and In Vitro Diagnostic Regulation were causing much concern in Europe’s markets, with timelines putting pressure on many companies and fears that an insufficient number of notified bodies would be designated by the necessary juncture. And while the disruption caused by the pandemic has pushed the MDR and IVDR deadlines back, it has also introduced many fresh challenges which the sector must be ready to confront. A panel of experts from leading medical device and diagnostic stakeholders discuss the current outlook for the regulations and how the sector can prepare itself.

  • The long term impact of travel restrictions on MDR/IVDR conformity assessments
  • Virtual audits as a solution to a 21st century problem
  • IVDR: A risk of shortages of tests?
  • Notified bodies as a key pillar within the medtech regulatory system: Capacity vs workload

Susana de Azevedo Wäsch, VP Quality Management & Regulatory Affairs, Ypsomed AG
Juliette Cook, Vice President Quality & Regulatory Affairs, Implantica
Claire Woodthorpe, COO and VP Europe, Lightpoint Medical
Martin Witte, Senior Director Strategic Business Development, TUV SUD

Susana de Azevedo Wäsch, VP Quality Management & Regulatory Affairs, Ypsomed AG    Juliette Cook, Vice President Quality & Regulatory Affairs, Implantica    Claire Woodthorpe, VP, Europe & COO, Lightpoint Medical    Martin Witte, Senior Director Strategic Business Development, TUV SUD


Making The Leap – What Does It Take To Be The Next Meddev Success Story?

Over the past two years, the medical device industry has faced unprecedented challenges ranging from the COVID-19 pandemic, supply chain disruptions, and rapid regulatory changes. However, the market continues to grow and is projected to be over $603 billion by 2023 worldwide with rapid expansions in digital health, the Internet of Medical Things (IoMT), robotics, public health, and a wave of technology advancements from 3D printing, AI and machine learning to bio batteries, wearables, and nanomedicine. We are entering a leapfrog phase in medical device development--exciting and unprecedented opportunities for innovative companies to lead and change the health of the world. Join this session for a deep dive into a year-on-year study of the state of the medical device industry, looking at the trends from before, during, and beyond the pandemic as we consider the future of medical devices

  • What does it take to be a medical device leader?
  • How do innovative companies navigate complex processes, meet regulatory requirements, build resilient talented teams and supply chains, and develop quality products for patients?
  • What are the key success factors medical device companies need to master at each stage from ideation to commercialization and scale?

Jon Speer, Founder, Greenlight Guru

Jon Speer, Founder, Greenlight Guru 300x


Digitisation Of Medtech – A Key Role In The Transformation Of Healthcare

Digital technology in the medtech space has the potential to capture huge value in healthcare systems around the world, with the benefit of improving care whilst also driving down costs. Thanks to a range of digital and date interventions, it is estimated cost savings could lie anywhere between an estimated $1.5 trillion and $3 trillion a year by 2030. However despite the increased adoption of digital interventions during the pandemic, many medtech companies have been slow to prepare for the new digital world of healthcare. A panel of experts discuss the exciting new opportunities for medtech companies and how best to take advantage of them.

  • Driving new sources of growth and improving patient care through digital solutions
  • How digital technology in medtech will best serve patients
  • Embracing new capabilities and operating models
  • Considering the complete operating ecosystem when designing digital driven solutions

Diana Saraceni, Managing Partner, Panakès Partners 
Gil Rabbie, Digital Solutions & Capability Development Leader, Boston Scientific
Per Vegard, CEO, CMR Surgical
Samih Al Mawass, Divisional Vice President EMEA Vascular, Abbott

Diana Saraceni, Co-Founder and General Partner, Panakes Partners    Gil Rabbie, Digital Solutions & Capability Development Leader, Boston Scientific    Per Vegard, CEO, CMR Surgical    Samih Al Mawass, Divisional Vice President EMEA Vascular, Abbott


Lunch Break


The Future Of Value-Based Healthcare & The Medtech Drivers In Its Creation

Health care delivery has been transformed over the past decade and medtech companies are driving its future. Following the global Covid-19 pandemic there has been extra impetus for system-wide change. A multi-stakeholder panel consider the differing definitions of value which are driving decision-making and deal-making across the medtech sector, the developing role of SMEs, providers, payers, and commercial leaders in creating superior clinical and economic outcomes across the medtech value chain, and how VBC can create a sustainable global health system, relieve funding pressures and deliver superior care.

  • Move to long term value based healthcare, offering products that protect from price erosion, focus on the customer and increase market share
  • Understanding the clinical context that devices are used in, to deliver wellness solutions
  • New funding models and payment models within medtech
  • Data use and interoperability, working with providers to manage AI-ethics, data privacy and cyber security
  • Trust and transparency within multinationals, to foster collaboration

Maarten Akkerman, Vice President Medical Affairs and Value-Based Healthcare, Medtronic
Frank Maddux, Global Chief Medical Officer, Fresenius Medical Care
Laura Niklason, CEO, Humacyte
Giles Hamilton, CEO, ODx Innovations

Maarten Akkerman, Vice President Medical Affairs and Value-Based Healthcare, Medtronic    Frank Maddux, Global Chief Medical Officer, Fresenius Medical Care    Laura Niklason, CEO, Humacyte    Giles Hamilton, CEO, ODx Innovations


Challenges & Considerations In Planning And Conducting A Clinical Study

  • Planning the most appropriate path to market
  • Alignment of protocol with regulation and guidelines
  • The challenges of submissions
  • Common pitfalls – an interactive Q&A

Linda Korthout, Director International Clinical Affairs, MCRA
Peter Bowness, Director, International Regulatory Affairs, MCRA; Former Senior Regulator, BSI

Linda Korthout, Director International Clinical Affairs, MCRA    Peter Bowness, Director, International Regulatory Affairs, MCRA; Former Senior Regulator, BSI


Going Beyond Solving Unmet Needs - The Role Of Product Design In Successful Medtech Commercialisation

Major advances in technology are driving innovation within healthcare, but at the heart and beginning of this journey, remains the product. Where once it was enough to create a solution to a problem, companies and innovators now need to look to the future from the very start in order for a product to ultimately succeed within an evolving and competitive market. A panel of specialists discuss the pitfalls and nuances within product design and the importance of always looking ahead

  • The importance of complete product lifecycle planning
  • Current and future manufacturing and supply chain challenges
  • Early commercial planning and building this into your product design strategy

Graeme Smith, CEO, Lightpoint Medical
Steve Swinson, Chairman of the Board, Comphya
Luke Hares, CTO, CMR Surgical

Graeme Smith, CEO, Lightpoint Medical    Steve Swinson, CEO, Comphya SA    Luke Hares, CTO, CMR Surgical

 

DOWNLOAD BROCHURE